TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cellectar Biosciences ( (CLRB) ) has provided an update.
On October 6, 2025, Cellectar Biosciences announced that the European Medicines Agency’s Scientific Advice Working Party advised that filing for a Conditional Marketing Authorization for iopofosine I 131, a treatment for post-BTKi refractory Waldenstrom macroglobulinemia, could be acceptable. If approved, iopofosine I 131 could be available in Europe by 2027, addressing a significant unmet medical need for around 35,000 to 45,000 patients. The company’s decision to file follows positive feedback on the patient population and data from the CLOVER WaM Phase 2 study. However, there is no guarantee of approval, and further trials may be required.
The most recent analyst rating on (CLRB) stock is a Hold with a $12.40 price target. To see the full list of analyst forecasts on Cellectar Biosciences stock, see the CLRB Stock Forecast page.
Spark’s Take on CLRB Stock
According to Spark, TipRanks’ AI Analyst, CLRB is a Underperform.
Cellectar Biosciences faces significant financial challenges with no revenue generation and heavy reliance on external financing. Technical indicators suggest a bearish trend, and the company’s valuation is weakened by negative earnings. Although the earnings call highlighted some clinical and regulatory progress, these are overshadowed by financial and operational setbacks, leading to a below-average overall stock score.
To see Spark’s full report on CLRB stock, click here.
More about Cellectar Biosciences
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of proprietary drugs for cancer treatment. The company leverages its Phospholipid Drug Conjugate™ (PDC) delivery platform to develop targeted cancer therapies, aiming for improved efficacy and safety.
Average Trading Volume: 115,651
Technical Sentiment Signal: Sell
Current Market Cap: $18.45M
See more insights into CLRB stock on TipRanks’ Stock Analysis page.